Genetic variations in host IL28B links to the detection of peripheral blood mononuclear cells-associated hepatitis C virus RNA in chronically infected patients

Journal of Viral Hepatitis

Volumn 20, Issue 4, 2013, Pages 263-272

  Angulo, J ^a   Pino, K ^a   Pavez, C ^b   Biel, F ^b   Labbe P ^b   Miquel, J F ^b   Soza, A ^b   Lopez Lastra M ^a  

^a UNIVERSIDAD ANDRÉS BELLO   (Chile)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

anti HCV therapy; HCV; IL28B; PBMC; PBMC associated HCV RNA

Indexed keywords

GENOMIC DNA; INTERLEUKIN 28B; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

5' UNTRANSLATED REGION; ADULT; ANTIVIRAL THERAPY; ARTICLE; DRUG TREATMENT FAILURE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; INTERLEUKINS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 84875166825     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12076     Document Type: Article

References (65)

1. Tsubota A, Fujise K, Namiki Y, Tada N,. Peginterferon and ribavirin treatment for hepatitis C virus infection. World J Gastroenterol 2011; 17 (4): 419-432.
2. Tencate V, Sainz B Jr, Cotler SJ, Uprichard SL,. Potential treatment options and future research to increase hepatitis C virus treatment response rate. Hepat Med 2011; 2010 (2): 125-145.
3. Ghany MG, Strader DB, Thomas DL, Seeff LB,. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49 (4): 1335-1374.
4. Vermehren J, Sarrazin C,. New HCV therapies on the horizon. Clin Microbiol Infect 2011; 17 (2): 122-134.
5. Ge D, Fellay J, Thompson AJ, et al,. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461 (7262): 399-401.
6. Suppiah V, Moldovan M, Ahlenstiel G, et al,. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41 (10): 1100-1104.
7. Tanaka Y, Nishida N, Sugiyama M, et al,. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41 (10): 1105-1109.
8. Thomas DL, Thio CL, Martin MP, et al,. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461 (7265): 798-801.
9. Thompson AJ, Muir AJ, Sulkowski MS, et al,. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139 (1): 120-129 e18.
10. Rauch A, Kutalik Z, Descombes P, et al,. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138 (4): 1338-1345 e1-7.
11. Hayes CN, Kobayashi M, Akuta N, et al,. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Gut 2011; 60 (2): 261-267.
12. Soza A, Everhart JE, Ghany MG, et al,. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology 2002; 36 (5): 1273-1279.
13. Blackard JT, Kemmer N, Sherman KE,. Extrahepatic replication of HCV: insights into clinical manifestations and biological consequences. Hepatology 2006; 44 (1): 15-22.
14. Zignego AL, Giannini C, Monti M, Gragnani L,. Hepatitis C virus lymphotropism: lessons from a decade of studies. Dig Liver Dis 2007; 39 (Suppl 1): S38-S45.
15. Hellings JA, van der Veen-du Prie J, Snelting-van Densen R, Stute R,. Preliminary results of transmission experiments of non-A, non-B hepatitis by mononuclear leucocytes from a chronic patient. J Virol Methods 1985; 10 (4): 321-326.
16. Maggi F, Fornai C, Vatteroni ML, et al,. Differences in hepatitis C virus quasispecies composition between liver, peripheral blood mononuclear cells and plasma. J Gen Virol 1997; 78 (Pt 7): 1521-1525.
17. Roque-Afonso AM, Ducoulombier D, Di Liberto G, et al,. Compartmentalization of hepatitis C virus genotypes between plasma and peripheral blood mononuclear cells. J Virol 2005; 79 (10): 6349-6357.
18. Vera-Otarola J, Barria MI, Leon U, et al,. Hepatitis C virus quasispecies in plasma and peripheral blood mononuclear cells of treatment naive chronically infected patients. J Viral Hepat 2009; 16 (9): 633-643.
19. Sung VM, Shimodaira S, Doughty AL, et al,. Establishment of B-cell lymphoma cell lines persistently infected with hepatitis C virus in vivo and in vitro: the apoptotic effects of virus infection. J Virol 2003; 77 (3): 2134-2146.
20. Bare P, Massud I, Parodi C, et al,. Continuous release of hepatitis C virus (HCV) by peripheral blood mononuclear cells and B-lymphoblastoid cell-line cultures derived from HCV-infected patients. J Gen Virol 2005; 86 (Pt 6): 1717-1727.
21. Revie D, Braich RS, Bayles D, et al,. Transmission of human hepatitis C virus from patients in secondary cells for long term culture. Virol J 2005; 2: 37.
22. Boisvert J, He XS, Cheung R, Keeffe EB, Wright T, Greenberg HB,. Quantitative analysis of hepatitis C virus in peripheral blood and liver: replication detected only in liver. J Infect Dis 2001; 184 (7): 827-835.
23. Natarajan V, Kottilil S, Hazen A, et al,. HCV in peripheral blood mononuclear cells are predominantly carried on the surface of cells in HIV/HCV co-infected individuals. J Med Virol 2010; 82 (12): 2032-2037.
24. Fujiwara K, Allison RD, Wang RY, et al,. Investigation of residual hepatitis C virus in presumed recovered subjects. Hepatology 2012; doi: 10.1002/hep.25921.
25. Gallegos-Orozco JF, Rakela J, Rosati MJ, Vargas HE, Balan V,. Persistence of hepatitis C virus in peripheral blood mononuclear cells of sustained viral responders to pegylated interferon and ribavirin therapy. Dig Dis Sci 2008; 53 (9): 2564-2568.
26. Pham TN, MacParland SA, Mulrooney PM, Cooksley H, Naoumov NV, Michalak TI,. Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol 2004; 78 (11): 5867-5874.
27. Radkowski M, Gallegos-Orozco JF, Jablonska J, et al,. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology 2005; 41 (1): 106-114.
28. Pham TN, Coffin CS, Churchill ND, Urbanski SJ, Lee SS, Michalak TI,. Hepatitis C virus persistence after sustained virological response to antiviral therapy in patients with or without past exposure to hepatitis B virus. J Viral Hepat 2012; 19 (2): 103-111.
29. Ibarra KD, Jain MK, Pfeiffer JK,. Host-based ribavirin resistance influences hepatitis C virus replication and treatment response. J Virol 2011; 85 (14): 7273-7283.
30. Inokuchi M, Ito T, Nozawa H, et al,. Lymphotropic hepatitis C virus has an interferon-resistant phenotype. J Viral Hepat 2012; 19 (4): 254-262.
31. Gong GZ, Lai LY, Jiang YF, He Y, Su XS,. HCV replication in PBMC and its influence on interferon therapy. World J Gastroenterol 2003; 9 (2): 291-294.
32. Pawlotsky JM, Bouvier-Alias M, Hezode C, Darthuy F, Remire J, Dhumeaux D,. Standardization of hepatitis C virus RNA quantification. Hepatology 2000; 32 (3): 654-659.
33. Barria MI, Vera-Otarola J, Leon U, et al,. Influence of extrahepatic viral infection on the natural history of hepatitis C. Ann Hepatol 2008; 7 (2): 136-143.
34. Barria MI, Gonzalez A, Vera-Otarola J, et al,. Analysis of natural variants of the hepatitis C virus internal ribosome entry site reveals that primary sequence plays a key role in cap-independent translation. Nucleic Acids Res 2009; 37 (3): 957-971.
35. Cariani E, Critelli R, Rota C, Luongo M, Trenti T, Villa E,. Interleukin 28B genotype determination using DNA from different sources: a simple and reliable tool for the epidemiological and clinical characterization of hepatitis C. J Virol Methods 2011; 178 (1-2): 235-238.
36. Miquel JF, Covarrubias C, Villaroel L, et al,. Genetic epidemiology of cholesterol cholelithiasis among Chilean Hispanics, Amerindians, and Maoris. Gastroenterology 1998; 115 (4): 937-946.
37. Nervi F, Miquel JF, Alvarez M, et al,. Gallbladder disease is associated with insulin resistance in a high risk Hispanic population. J Hepatol 2006; 45 (2): 299-305.
38. Olmos P, Bastias MJ, Vollrath V, et al,. C(-106)T polymorphism of the aldose reductase gene and the progression rate of diabetic retinopathy. Diabetes Res Clin Pract 2006; 74 (2): 175-182.
39. Venegas M, Villanueva RA, Gonzalez K, Brahm J,. IL28B polymorphisms associated with therapy response in Chilean chronic hepatitis C patients. World J Gastroenterol 2011; 17 (31): 3636-3639.
40. Soza A, Arrese M, Gonzalez R, et al,. Clinical and epidemiological features of 147 Chilean patients with chronic hepatitis C. Ann Hepatol 2004; 3 (4): 146-151.
41. Soza A, Lopez-Lastra M,. Hepatitis C in Chile: burden of the disease. Rev Med Chil 2006; 134 (6): 777-788.
42. Farci P, Purcell RH,. Clinical significance of hepatitis C virus genotypes and quasispecies. Semin Liver Dis 2000; 20 (1): 103-126.
43. Basaras M, de las Heras B, Garcia Bengoechea M, Gallego L, Arrese E, Cisterna R,. Detection of hepatitis C virus RNA in serum and peripheral blood mononuclear cells in patients with chronic hepatitis C treated with interferon alpha. Eur J Clin Microbiol Infect Dis 1996; 15 (11): 887-890.
44. Ramirez S, Perez-Del-Pulgar S, Carrion JA, et al,. Hepatitis C virus compartmentalization and infection recurrence after liver transplantation. Am J Transplant 2009; 9 (7): 1591-1601.
45. Qian C, Camps J, Maluenda MD, Civeira MP, Prieto J,. Replication of hepatitis C virus in peripheral blood mononuclear cells. Effect of alpha-interferon therapy. J Hepatol 1992; 16 (3): 380-383.
46. Moonka DK, Henzel BS, Gutekunst K, O'Brien CB,. Quantitative assessment of hepatitis C virus RNA in peripheral blood mononuclear cells during therapy with interferon-alpha2a. J Viral Hepat 1998; 5 (1): 27-33.
47. Cribier B, Uhl G, Schmitt C, et al,. Follow-up of hepatitis C virus RNA in peripheral blood mononuclear cells during interferon therapy. Arch Virol 1999; 144 (2): 355-364.
48. Page EE, Cox A, Atkins M, Nelson MR,. Clearance of hepatitis C virus RNA from serum in HIV/hepatitis C virus coinfection indicates eradication from peripheral blood mononuclear cells. AIDS 2011; 24 (9): 1267-1271.
49. Perrella A, Sbreglia C, Atripaldi L, Esposito C, D'Antonio A, Perrella O,. Rapid virological response in peripheral blood mononuclear cells with an increase of hepatitis C virus-specific interferon-gamma production predisposes to sustained virological response in patients with chronic hepatitis C genotype 1 undergoing treatment with pegylated-interferon alpha 2a plus ribavirin. Scand J Gastroenterol 2010; 45 (2): 250-255.
50. Maylin S, Martinot-Peignoux M, Moucari R, et al,. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 2008; 135 (3): 821-829.
51. Chary A, Winters MA, Eisen R, Knight TH, Asmuth DM, Holodniy M,. Quantitation of hepatitis C virus RNA in peripheral blood mononuclear cells in HCV-monoinfection and HIV/HCV-coinfection. J Med Virol 2012; 84 (3): 431-437.
52. Kowala-Piaskowska A, Mozer-Lisewska I, Figlerowicz M, Sluzewski W,. Influence of the presence of HCV-RNA in peripheral blood mononuclear cells on the clinical course of chronic hepatitis C in children. Eur J Epidemiol 2007; 22 (5): 343-348.
53. Ryder SD, Irving WL, Jones DA, Neal KR, Underwood JC,. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut 2004; 53 (3): 451-455.
54. Saleh MG, Tibbs CJ, Koskinas J, et al,. Hepatic and extrahepatic hepatitis C virus replication in relation to response to interferon therapy. Hepatology 1994; 20 (6): 1399-1404.
55. Lohr HF, Goergen B, Meyer zum Buschenfelde KH, Gerken G,. HCV replication in mononuclear cells stimulates anti-HCV-secreting B cells and reflects nonresponsiveness to interferon-alpha. J Med Virol 1995; 46 (4): 314-320.
56. Tillmann HL, Thompson AJ, Patel K, et al,. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 2010; 139 (5): 1586-1592, 92 e1.
57. McCarthy JJ, Li JH, Thompson A, et al,. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010; 138 (7): 2307-2314.
58. Hayes CN, Imamura M, Aikata H, Chayama K,. Genetics of IL28B and HCV-response to infection and treatment. Nat Rev Gastroenterol Hepatol 2012; 9 (7): 406-417.
59. Laskus T, Radkowski M, Piasek A, et al,. Hepatitis C virus in lymphoid cells of patients coinfected with human immunodeficiency virus type 1: evidence of active replication in monocytes/macrophages and lymphocytes. J Infect Dis 2000; 181 (2): 442-448.
60. Kotenko SV,. IFN-lambdas. Curr Opin Immunol 2011; 23 (5): 583-590.
61. Lasfar A, Lewis-Antes A, Smirnov SV, et al,. Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma. Cancer Res 2006; 66 (8): 4468-4477.
62. Honda M, Sakai A, Yamashita T, et al,. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010; 139 (2): 499-509.
63. Dill MT, Duong FH, Vogt JE, et al,. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 2010; 140 (3): 1021-1031.
64. Marukian S, Andrus L, Sheahan TP, et al,. Hepatitis C virus induces interferon-lambda and interferon-stimulated genes in primary liver cultures. Hepatology 2011; 54 (6): 1913-1923.
65. Bauhofer O, Ruggieri A, Schmid B, Schirmacher P, Bartenschlager R,. Persistence of HCV in quiescent hepatic cells under conditions of an interferon-induced antiviral response. Gastroenterology 2012; 143 (2): 429-438 e8.